SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-005215
Filing Date
2016-05-03
Accepted
2016-05-03 17:01:25
Documents
43
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nvls-20160331x10q.htm 10-Q 886553
2 EX-10.1 nvls-20160331ex1019ec98b.htm EX-10.1 221637
3 EX-10.2 nvls-20160331ex102d0dd40.htm EX-10.2 123152
4 EX-10.3 nvls-20160331ex10391e7a8.htm EX-10.3 120668
5 EX-31.1 nvls-20160331ex3112bfeb6.htm EX-31.1 19071
6 EX-31.2 nvls-20160331ex312223689.htm EX-31.2 19083
7 EX-32.1 nvls-20160331ex321e613e5.htm EX-32.1 9734
  Complete submission text file 0001558370-16-005215.txt   3291100

Data Files

Seq Description Document Type Size
8 EX-101.INS nvls-20160331.xml EX-101.INS 564623
9 EX-101.SCH nvls-20160331.xsd EX-101.SCH 15958
10 EX-101.CAL nvls-20160331_cal.xml EX-101.CAL 22843
11 EX-101.DEF nvls-20160331_def.xml EX-101.DEF 46441
12 EX-101.LAB nvls-20160331_lab.xml EX-101.LAB 168795
13 EX-101.PRE nvls-20160331_pre.xml EX-101.PRE 117807
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37449 | Film No.: 161616258
SIC: 2834 Pharmaceutical Preparations